- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Generalised myasthenia gravis (gMG)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Efgartigimod alfa – March 2025
Efgartigimod alfa; Solution concentrate of I.V. infusion 400 mg in 20 mL; Vyvgart®
Last updated
12 March 2025